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In the Netherlands during 1993–2001, multidrug-re-
sistant tuberculosis among newly diagnosed patients was 
more frequent in those with HIV coinfection (5/308, 1.6%) 
than in those with no HIV infection (39/646, 0.6%; adjusted 
odds ratio 3.43, p = 0.015). Four of the 5 patients coinfected 
with multidrug-resistant tuberculosis and HIV were foreign-
born. DNA ﬁ  ngerprint analysis suggested that transmission 
had occurred outside the Netherlands.
H
IV infection strongly increases the risk for tuberculo-
sis (TB) infection: TB disease occurs in 7%–10% of 
patients with HIV infection each year (1). The increase in 
numbers of patients with both HIV infection and TB has 
raised the potential for increasing transmission of drug-re-
sistant Mycobacterium tuberculosis strains (2).
Reports on associations of HIV coinfection and drug 
resistance among patients with TB have been contradictory. 
Some studies found strongly increased risks for multidrug-
resistant TB (MDR TB) among patients coinfected with TB 
and HIV (3–7), whereas other studies found no increased 
risk (8–11). Population-based data are limited, however, in 
particular from low-prevalence countries. We report on a 
population-based study of anti-tuberculosis drug resistance 
patterns and associations with HIV infection in the Nether-
lands during 1993–2001. 
The Study
Patient data were obtained from the Netherlands Tu-
berculosis Register (NTR), which contains data on all TB 
cases since 1993 reported by TB control departments of 
municipal health services. Data on drug susceptibility were 
obtained from the National Tuberculosis Reference Labo-
ratory (National Institute of Public Health and the Environ-
ment, Bilthoven, the Netherlands), which performs drug-
susceptibility testing (DST) and restriction fragment length 
polymorphism (RFLP) typing on all M. tuberculosis com-
plex strains isolated from patients in the Netherlands. DST 
is performed according to an absolute concentration method 
on 7H10 agar, with a proportional cut-off (12). RFLP typ-
ing is based on the standardized method (13). Laboratory 
records were matched to NTR records by a combination of 
postal code, date of birth, and sex.
In the NTR, HIV infection is recorded as a response 
option on the item on impaired immunity. Patients with a 
record of impaired immunity due to HIV infection were 
considered HIV positive. If immunity was reported to be 
impaired because of other causes than HIV infection, or if 
immune status was unknown, HIV status was considered 
negative. If the item on impaired immunity was missing 
(not ﬁ  lled out), the record was excluded from the analysis.
In the analysis, the association was determined be-
tween HIV status and resistance to various drugs and com-
binations of drugs used to treat TB. MDR TB was deﬁ  ned 
as resistance of M. tuberculosis to at least isoniazid and ri-
fampin. DST results before start of treatment were included 
unless cultures had only been taken during treatment. Pa-
tients were categorized as either previously treated or new 
(i.e., previously untreated). Previous treatment was deﬁ  ned 
as a history of TB treatment for >4 weeks, a sputum sample 
obtained during treatment, or both.
For comparison of categorical variables, signiﬁ  cance 
testing was done by χ2 test with continuity correction or by 
2-sided Fisher exact test as appropriate. Multivariate analy-
sis was conducted by logistic regression. A p value <0.05 
was considered statistically signiﬁ  cant unless stated other-
wise. Analyses were conducted with SPSS version 12.0.1 
(SPSS Inc., Chicago, IL, USA).
During the study period, 13,943 TB cases were report-
ed to NTR (57% in foreign-born patients), including 8,450 
persons with positive M. tuberculosis cultures. Of the case-
patients with positive cultures, 7,354 were identiﬁ  ed in the 
laboratory database (87.0%). Excluded were 264 (3.6%) 
of  7,354 case-patients because of missing information on 
impaired immunity, which left 7,090 case-patients for the 
analysis. No signiﬁ  cant differences between included and 
excluded case-patients were found in age, sex, national-
ity, localization of disease, place of residence, risk groups, 
or year of diagnosis. More included than excluded case-
patients had received a TB diagnosis in a hospital, 5,500 
(78%) versus 4,310 (62%), respectively (p = 0.034). 
HIV infection was reported in 329 (4.6%) of the 7,090 
included case-patients. Of these, 232 (71%) were male, 198 
(60%) were of foreign origin, 118 (36%) were of Dutch 
origin, and 13 (4%) were of unknown origin. The 198 case-
patients of foreign origin included 128 (41%) patients from 
Africa and 24 (8%) from industrialized countries; the re-
maining 49 (14%) patients were from Asia and Central and 
South America.
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Of the 7,090 case-patients included in the study, 6,775 
(95.6%) were new and 315 (4.4%) were previously treated. 
Among the new cases, drug resistance was reported in 817 
(12.1%); isoniazid resistance was reported in 449 (6.6%), 
rifampin resistance in 51 (0.8%), and multidrug resistance 
in 44 (0.7%). Multidrug resistance was signiﬁ  cantly associ-
ated with HIV infection both before (odds ratio [OR] 2.78, 
p = 0.033) and after adjustment by multivariate analysis 
for age, sex, and continent of origin (adjusted OR 3.43, p = 
0.015). In addition, near-signiﬁ  cant associations with HIV 
infection were observed for resistance to isoniazid (OR 
1.50, 95% conﬁ  dence interval [CI] 0.99–2.26) and resis-
tance to rifampin (OR 2.35, 95% CI 0.82–6.24) (Table 1).
Among the 315 previously treated patients, drug resis-
tance was reported in 68 (21.6%); isoniazid resistance was 
reported in 52 (16.5%), rifampin resistance in 19 (6.0%), 
and multidrug resistance in 17 (5.4%). HIV infection was 
signiﬁ  cantly associated with any rifampin resistance (OR 
4.12, CI 1.01–15.67, p<0.05) (Table 2). Monoresistance to 
rifampin was found in 2 previously treated patients; both 
were HIV infected. 
The 5 new HIV-infected MDR TB patients (4 men, 1 
woman; age range 22–31 years) originated from the Neth-
erlands, Liberia, Angola, South Africa, and Portugal. Four 
had diagnoses of pulmonary TB and 1 extrapulmonary TB. 
None had a known history of intravenous drug use. Two 
patients completed treatment, 2 died during treatment, and 
1 continued treatment at an unknown location.
The 2 previously treated HIV-infected MDR TB pa-
tients (both women, ages 28 and 43 years) originated from 
Europe. Pulmonary TB was diagnosed for both; 1 was an 
intravenous drug user. One died during treatment, and the 
other was lost to follow-up.
Each of the 7 patients with both MDR TB and HIV in-
fection had different RFLP patterns. Four of these patients, 
all new, shared an RFLP pattern with >1 other patient in the 
database. For 1 of these, the cluster included other MDR 
TB patients. Transmission could have occurred from this 
patient with MDR TB and HIV infection to 2 other patients 
without HIV infection whose TB had been diagnosed in the 
same year. The same patient, whose infecting strain was 
resistant to isoniazid, rifampin, and streptomycin, could 
have acquired the TB infection in the Netherlands from an 
African patient with HIV infection who had received a di-
agnosis of TB 3 years earlier and harbored a strain resistant 
to isoniazid and streptomycin. For the other 3 clustered pa-
tients, the resistance patterns or date of entry into the coun-
try made transmission to or from other patients within the 
Netherlands impossible.
In the 2 cases of monoresistance of TB to rifampin, 
the isolates were obtained before treatment from patients 
with HIV infection originating from Cape Verde and So-
malia. Both had combined pulmonary and extrapulmonary 
TB and had been treated before in the Netherlands. One had 
completed 6 months of treatment; for the other, treatment 
completion was not recorded.
Conclusions
Overall, MDR TB occurred in 5 (2.5%) of 198 for-
eign-born patients with TB and HIV infection, compared 
with 2 (1.7%) of 118 Dutch-born patients with TB and HIV 
coinfection (p = 0.730). We found low prevalence of mul-
tidrug resistance among patients with TB, in accordance 
with an earlier study that covered a shorter period (8). In 
the Netherlands, transmission of MDR TB has been rare. 
During the study period, single secondary MDR TB cases, 
as conﬁ  rmed by RFLP typing, were documented in only 
2 instances, 1 nosocomial (M. Sebek, pers. comm.). This 
may be related to the presence of a system of drug resis-
tance surveillance with national coverage, active contact 
Table 1. Association between HIV infection and primary drug resistance among new tuberculosis patients, the Netherlands,  
1993–2001*
No. (%) HIV negative 
(n = 6,467)
No. (%) HIV positive 
(n = 308)
OR (95% CI) 
(unadjusted) p value† 
Fully susceptible 5,695 (88.1) 263 (85.4) 1.00
Resistant to 1 drug 544 (8.4) 29 (9.4) 1.15 (0.76–1.74) 0.542
Resistant to 2 drugs 193 (3.0) 11 (3.6) 1.23 (0.63–2.36) 0.622
Resistant to 3 drugs 24 (0.4) 5 (1.6) 4.51 (1.50–12.57) 0.001
Resistant to 4 drugs 11 (0.2) 0 – –
Any resistance  772 (11.9) 45 (17.1) 1.26 (0.90–1.77) 0.188
Any resistance to:
Isoniazid 420 (6.5)  29 (9.4)  1.50 (0.99–2.26)  0.059
Rifampin 46 (0.7)  5 (1.6)  2.35 (0.82–6.24)  0.075
Streptomycin  538 (8.3)  31 (10.1)  1.25 (0.83–1.86)  0.303
Ethambutol 42 (0.6)  1 (0.3)  0.52 (0.03–3.49)  1.000
Multidrug resistance‡ 39 (0.6) 5 (1.6)  2.78 (1.09–7.10) 0.033
*New patients are defined as those not previously treated for tuberculosis. OR, odds ratio; CI, confidence interval. 
†p value determined by Fisher exact test or χ
2 test (Yates corrected), as appropriate. 
‡Resistant to at least isoniazid and rifampin. DISPATCHES
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tracing around infectious TB cases, and directly observed 
treatment of patients with MDR TB in specialized centers 
under strict respiratory isolation.
Only 7 cases of MDR TB occurred among 329 patients 
with HIV infection during this 9-year period (2.1%). De-
spite this small number, MDR TB was signiﬁ  cantly more 
frequent among previously untreated patients with TB and 
HIV infection than among those without HIV infection. 
Even though the results were adjusted, at least partially, 
for origin of the patient, non-Dutch origin appears to play 
an important role in this association. Of the 5 patients with 
new TB and HIV infection, 4 were foreign-born, includ-
ing 3 from sub-Saharan Africa. Because transmission in 
the Netherlands could be ruled out in 4 of the 5 new cases, 
most if not all of these infections were acquired abroad. 
The MDR TB infections in these patients may have been 
acquired in institutional settings such as hospitals, but data 
on the pre-immigration history were lacking.
Four (19%) of 21 case-patients with previously treated 
TB and HIV infection had rifampin-resistant isolates, in-
cluding 2 (10%) that were rifampin monoresistant. Acqui-
sition of monoresistance to rifampin is associated with HIV 
infection and may be related to intestinal malabsorption, 
intermittent treatment with rifabutin, and drug interactions 
(14,15). In the patients in our study, the contribution of 
these factors could not be established.
In conclusion, among new TB patients in the Nether-
lands, multidrug resistance is associated with HIV infec-
tion, predominantly as an imported disease. In patients with 
HIV infection who have previously been treated for TB, 
the possibility of rifampin resistance should be considered. 
Routine surveillance of resistance to anti-TB drugs will im-
prove timely recognition of MDR TB cases and help pre-
vent further transmission.
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Table 2. Prevalence of secondary drug resistance among 
previously treated tuberculosis patients, the Netherlands,  
1993–2001*
No. (%) HIV 
negative (n = 294)
No. (%) HIV 
positive (n = 21)
Fully susceptible 232 (78.9) 15 (71.4)
Resistant to 1 drug  34 (11.9) 4 (19.0) 
Isoniazid 20 (6.8)  2 (9.5) 
Rifampin 0 2 (9.5)
Streptomycin 14 (4.8) 0
Resistant to 2 drugs 17 (5.8) 0
Resistant to 3 drugs 4 (1.4) 0
Resistant to 4 drugs 7 (2.4) 2 (9.5)
Any resistance  62 (21.1) 6 (28.6)
Any resistance to 
Isoniazid 48 (16.3)  4 (19.0) 
Rifampin 15 (5.1)  4 (19.0)* 
Streptomycin  36 (12.2)  2 (9.5) 
Ethambutol 9 (3.1)  2 (9.5) 
Multidrug resistance† 15 (5.1) 2 (9.5)
*Unadjusted odds ratio 4.12 (95% confidence interval 1.01–15.67, p = 
0.036). 
†Resistant to at least isoniazid and rifampin. 